Ubs Group Ag Annovis Bio, Inc. Transaction History

Ubs Group Ag

$611 Billion
Q3 2025

A detailed history of Ubs Group Ag transactions in Annovis Bio, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 633 shares of ANVS stock, worth $1,462. This represents 0.0% of its overall portfolio holdings.

Number of Shares

633

Previous 26,317 97.59%

Holding current value

$1,462

Previous $57,000 98.25%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	SELL	$1.97 - $2.93 $50,597 - $75,254	-25,684 Reduced 97.59%	633 $1,000
Q2 2025 Aug 14, 2025	SELL	$1.22 - $3.24 $164,161 - $435,971	-134,559 Reduced 83.64%	26,317 $57,000
Q1 2025 May 13, 2025	BUY	$1.5 - $5.39 $168,210 - $604,434	112,140 Added 230.1%	160,876 $241,000
Q4 2024 Feb 14, 2025	BUY	$4.37 - $9.87 $204,904 - $462,794	46,889 Added 2538.66%	48,736 $245,000
Q3 2024 Nov 14, 2024	SELL	$5.27 - $15.46 $58,723 - $172,270	-11,143 Reduced 85.78%	1,847 $14,000
Q2 2024 Aug 13, 2024	BUY	$4.82 - $18.01 $59,719 - $223,143	12,390 Added 2065.0%	12,990 $74,000
Q4 2023 Feb 09, 2024	BUY	$5.55 - $19.62 $2,775 - $9,810	500 Added 500.0%	600 $11,000
Q2 2023 Aug 11, 2023	BUY	$11.95 - $16.31 $1,195 - $1,630	100 New	100 $1,000
Q2 2022 Aug 10, 2022	BUY	$8.61 - $13.87 $3,564 - $5,742	414 New	414 $5,000
Q1 2022 May 16, 2022	SELL	$11.84 - $19.78 $29,375 - $49,074	-2,481 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$17.58 - $37.67 $36,707 - $78,654	2,088 Added 531.3%	2,481 $44,000
Q3 2021 Nov 15, 2021	SELL	$30.95 - $120.97 $23,986 - $93,751	-775 Reduced 66.35%	393 $12,000
Q2 2021 Aug 13, 2021	BUY	$21.55 - $96.1 $25,170 - $112,244	1,168 New	1,168 $100,000

Others Institutions Holding ANVS

# of Institutions

Shares Held

2.03M

Call Options Held

167K

Put Options Held

97.2K

View Full List

About Annovis Bio, Inc.

Ticker ANVS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 8,163,920
Market Cap $18.9M
Description
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...

More about ANVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account